SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
RANI

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$0.51-$0.07 (-11.97%)
 
Market cap
$33.4M
Insider Score
Health Score
Analyst consensus
Listed since
Jul 30, 2021
Market Cap$33.39M-69.2%
Revenue (ttm)$6.58M+448.7%
Net Income-$32.46M-14.6%
EPS-$0.19+76.1%
Shares Out65.32M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume459,003
Open$0.58
Previous Close$0.58
Day's Range$0.51 - $0.58
52-Week Range$0.39 - $3.87
Beta0.68
AnalystsBuy
Price Target$15.67(+2965.94%)
Earnings DateMar 25, 2027

About RANI

Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.

Address
2051 Ringwood Avenue, San Jose, CA, 95131, US
Market Cap
33 million
Employees
70
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$15.72M
Bought
$1.31M

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
2 Buy0 Hold0 Sell

2 firms rating RANI in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Weak
From RANI’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-11.97%
5 Days
+0.22%
1 Month
-13.02%
6 Months
-52.23%
1 Year
-69.21%

$RANI stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in RANI holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by RANI's directors and management

Net Shares Purchased by Insiders−4M−2M02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

RANI Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New RANI patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to RANI from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in RANI

VTIVanguard Morningstar Total Stock Market ETF$1.70M
VXFVanguard Extended Market ETF$513.22K
IBBQInvesco Nasdaq Biotechnology ETF$5.43K
BIBProShares Ultra Nasdaq Biotechnology$2.48K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from RANI’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
10.81
Analyst Ratings
40% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
3
Sells
4
Buy Value
$1.31M
Distinct Buyers
2

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

IBBQInvesco Nasdaq Biotechnology ETF0.00%
BIBProShares Ultra Nasdaq Biotechnology0.00%

Weight is the stock’s share of each fund’s holdings.